Cited by 148Diabetes Management and ResearchDiabetes Management and EducationDiabetes Treatment and Management

Glucose Self-monitoring in Non–Insulin-Treated Patients With Type 2 Diabetes in Primary Care Settings: A Randomized Trial

Open access
Young, Laura A., Buse, John B., Weaver, Mark A., Vu, Maihan B., Mitchell, C. Madeline, Blakeney, Tamara, Grimm, Kimberlea, Rees, Jennifer +3 more·2017·JAMA Internal Medicine

Abstract

Importance: The value of self-monitoring of blood glucose (SMBG) levels in patients with non-insulin-treated type 2 diabetes has been debated. Objective: To compare 3 approaches of SMBG for effects on hemoglobin A1c levels and health-related quality of life (HRQOL) among people with non-insulin-treated type 2 diabetes in primary care practice. Design, Setting, and Participants: The Monitor Trial study was a pragmatic, open-label randomized trial conducted in 15 primary care practices in central North Carolina. Participants were randomized between January 2014 and July 2015. Eligible patients with type 2 non-insulin-treated diabetes were: older than 30 years, established with a primary care physician at a participating practice, had glycemic control (hemoglobin A1c) levels higher than 6.5% but lower than 9.5% within the 6 months preceding screening, as obtained from the electronic medical record, and willing to comply with the results of random assignment into a study group. Of the 1032 assessed for eligibility, 450 were randomized. Interventions: No SMBG, once-daily SMBG, and once-daily SMBG with enhanced patient feedback including automatic tailored messages delivered via the meter. Main Outcomes and Measures: Coprimary outcomes included hemoglobin A1c levels and HRQOL at 52 weeks. Results: A total of 450 patients were randomized and 418 (92.9%) completed the final visit. There were no significant differences in hemoglobin A1c levels across all 3 groups (P = .74; estimated adjusted mean hemoglobin A1c difference, SMBG with messaging vs no SMBG, -0.09%; 95% CI, -0.31% to 0.14%; SMBG vs no SMBG, -0.05%; 95% CI, -0.27% to 0.17%). There were also no significant differences found in HRQOL. There were no notable differences in key adverse events including hypoglycemia frequency, health care utilization, or insulin initiation. Conclusions and Relevance: In patients with non-insulin-treated type 2 diabetes, we observed no clinically or statistically significant differences at 1 year in glycemic control or HRQOL between patients who performed SMBG compared with those who did not perform SMBG. The addition of this type of tailored feedback provided through messaging via a meter did not provide any advantage in glycemic control. Trial Registration: clinicaltrials.gov Identifier: NCT02033499.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamainternmed.2017.1233

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In people with type 2 diabetes not using insulin, routine glucose monitoring is of limited additional clinical benefit while adding burden and cost.

    “In people with type 2 diabetes not using insulin, routine glucose monitoring is of limited additional clinical bene fi t while adding burden and cost (54,55).”

    From Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2022) · cites this paper as [55]

    The Abstract reports no clinically or statistically significant improvement in glycemic control or health-related quality of life after one year of self-monitoring in non-insulin-treated patients. The Discussion raises possible user fatigue, but our copy does not establish that monitoring adds burden or cost; the cost-effectiveness study appears only in the References. (LLM, conf=0.82)

    Experimental — accuracy not yet measured
  • A pragmatic, open-label randomized trial found no clinically or statistically significant differences at 1 year in glycemic control (as assessed by HbA 1c) or health-related quality of life between patients who performed BGM, with or without enhanced feedback, and those who did not.

    “The study found no clinically or statistically significant differences at 1 year in glycemic control (as assessed by HbA 1c ) or health-related quality of life between patients who performed BGM, with or without enhanced feedback, and those who did not.”
  • In people with type 2 diabetes not taking insulin, routine glucose monitoring may have limited additional clinical benefit; by itself, even with education, it has shown limited improvement in outcomes.

    “In people with type 2 diabetes not taking insulin, routine glucose monitoring may be of limited additional clinical benefit.By itself, even when combined with education, this practice has shown limited improvement in outcomes (31).”

    From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [31]

  • A trial of once-daily BGM with enhanced feedback through messaging found no clinically or statistically significant change in A1C at 1 year.

    “A trial of once-daily BGM that included enhanced feedback from people with diabetes through messaging found no clinically or statistically significant change in A1C levels at 1 year (31).”

    From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [31]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [41]41. Wofford JL, Martin MJ, Campos CL. Eliminating routine glucometer readings in the office setting: correcting a foolish consistency. JAMA Intern Med. 2016;176(11):1721-1722. doi:10.1001/jamainternmed .2016.5883 · DOI

Cited by

Sorted by citations

Authors
Young, L. A., Buse, J. B., Weaver, M. A., Vu, M. B., Mitchell, C. M., Blakeney, T., Grimm, K., Rees, J., Niblock, F., Donahue, K. E., & for the Monitor Trial Group
Affiliations
University of North Carolina at Chapel Hill (US)
Venue
JAMA Internal Medicine
Published
2017-07-01
Volume
177
Issue
7
Pages
920
ISSN
2168-6106 (ISSN-L)
OpenAlex
W2623217224
Cited by
148
References
38
Citations by year
2026: 7 · 2025: 9 · 2024: 9 · 2023: 14 · 2022: 15 · 2021: 29 · 2020: 18 · 2019: 19 · 2018: 17 · 2017: 11
FWCI
14.04
Type
journal article
Language
en
Open access
Locations
  • JAMA Internal Medicine (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • American Diabetes Association (UL1TR001111)
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • AstraZeneca
  • GlaxoSmithKline
  • Sanofi
  • Intarcia Therapeutics
  • Halozyme
  • AstraZeneca HealthCare Foundation
  • MacroGenics
  • Novo Nordisk
  • Astellas Pharma
  • National Institutes of Health (UL1TR002489)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
self-monitoring of blood glucose, type 2 diabetes, non-insulin-treated diabetes, glycemic control, HbA1c, health-related quality of life, patient feedback, message tailoring, blood glucose meters, primary care, hypoglycemia, insulin initiation, diabetes self-management education
MeSH terms
Adult, Aged, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, North Carolina, Outcome and Process Assessment, Health Care, Primary Health Care, Quality of Life, Blood Glucose Self-Monitoring, Disease Management

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review